Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP12 | P39900 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | MMP14 | P50281 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
| ▸ | ANPEP | P15144 | 1/20 | 0.43 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14968476 | 1.00 | TSHR (0.49) | TSHRDPP4MMP2MMP9MMP12 | |
| SCHEMBL14402642 | 1.00 | TSHR (0.49) | TSHRDPP4MMP2MMP9MMP12 | |
| SCHEMBL4799370 | 0.89 | MMP2 (0.55) | TSHRDPP4MMP2MMP9MMP12 | |
| SCHEMBL14402447 | 0.88 | SIGMAR1 (0.49) | SLC6A2SLC6A4SLC6A3KCNH2SIGMAR1 | |
| SCHEMBL3652085 | 0.88 | SIGMAR1 (0.49) | SLC6A2SLC6A4SLC6A3KCNH2SIGMAR1 | |
| SCHEMBL6930924 | 0.88 | CYP1A2 (0.47) | TSHRDPP4MMP2MMP9MMP12 | |
| SCHEMBL2307042 | 0.86 | CSNK1E (0.53) | SIGMAR1 | |
| SCHEMBL1678631 | 0.86 | TRPA1 (0.55) | KCNH2SIGMAR1 | |
| SCHEMBL22099432 | 0.86 | TSHR (0.41) | TSHRDPP4MMP2MMP9MMP12 | |
| SCHEMBL2524872 | 0.85 | DPP4 (0.49) | TSHRDPP4MMP2MMP9MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1141196-A | Application of quinoxalines in combination with protease inhibitors as medicaments | BAYER AG (DE) | 1997-01-29 | — | — | CN | claimed |
| EP-1847533-B1 | SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2013-08-14 | — | — | EP | disclosed |
| US-20110086868-A1 | SPECIFIC INHIBITORS FOR VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS | NOVA SOUTHEASTERN UNIVERSITY (US) | 2011-04-14 | — | — | US | disclosed |
| WO-2010123932-A1 | COMPOSITIONS AND METHODS FOR FERMENTATION OF BIOMASS | QTEROS, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
| CN-100584833-C | Ritonavir analogous compound useful as retroviral protease inhibitor, preparation of the ritonavir analogous compound and pharmaceutical composition for the ritonavir analogous compound. | CRISTALIA PROD QUIMICOS FARM | 2010-01-27 | — | — | CN | disclosed |
| EP-1481961-B1 | PROCESS FOR PRODUCING (R)-3-HYDROXY-3-(2-PHENYLETHYL)HEXANOIC ACID AND ITS INTERMEDIATE | SUMITOMO CHEMICAL CO (JP) | 2009-11-25 | — | — | EP | disclosed |
| CN-100528828-C | Production method of racemiation3-hydroxy-3- (2-phenylethyl) hexanoic acid C1-6 alkyl ester | SUMIKA FINE CHEMICALS CO LTD (JP) | 2009-08-19 | — | — | CN | disclosed |
| EP-1894912-B1 | Process for producing racemic 3-hydroxy-3-(2-phenylethyl) hexanoic acid ester | SUMITOMO CHEMICAL CO (JP) | 2009-08-05 | — | — | EP | disclosed |
| US-7531533-B2 | 6-Membered heterocyclic compound and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-05-12 | — | — | US | disclosed |
| EP-1894912-A1 | Process for producing racemic 3-hydroxy-3-(2-phenylethyl) hexanoic acid ester | Sumitomo Chemical Company, Limited (JP) | 2008-03-05 | — | — | EP | disclosed |
| CN-1301244-C | Process for producing -3-hydroxy-3- (2-phenylethyl) hexanoic acid and intermediates thereof | SUMITOMO CHEMICAL CO (JP) | 2007-02-21 | — | — | CN | disclosed |
| US-7038075-B2 | Production method of racemic 3-hydroxy-3-(2-phenylethyl)hexanoic acid C1-6 alkyl ester | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-05-02 | — | — | US | disclosed |
| CN-1617846-A | Process for producing -3-hydroxy-3- (2-phenylethyl) hexanoic acid and intermediates thereof | SUMITOMO CHEMICAL CO (JP) | 2005-05-18 | — | — | CN | disclosed |
| EP-1481961-A1 | PROCESS FOR PRODUCING (R)-3-HYDROXY-3-(2-PHENYLETHYL)HEXANOIC ACID AND ITS INTERMEDIATE | Sumitomo Chemical Company, Limited (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-20040138496-A1 | Production method of (R)-3- hydroxy-3-(2-phenylethyl)hexanoic acid and intermediate thereof | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| US-6683207-B2 | RESOLUTION USING 1-AMINO-1-PHENYLETHANE DERIVATIVE | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 2004-01-27 | — | — | US | disclosed |
| US-20030176507-A1 | Production method of (R) -3 hydroxy-3- (2-phenylethyl) hexanoic acid and intermediate thereof | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
| US-20030114352-A1 | Depot preparations | SYMRISE GMBH & CO. KG (DE) | 2003-06-19 | — | — | US | disclosed |
| WO-2001082919-A2 | METHODS OF AND COMPOUNDS FOR INHIBITING CALPAINS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-11-08 | — | — | WO | disclosed |
| EP-0599862-B1 | MOISTURE-SCAVENGING IMINOALCOHOL-OXAZOLIDINE MIXTURES | ANGUS CHEMICAL (US) | 1995-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138496-A1 | Production method of (R)-3- hydroxy-3-(2-phenylethyl)hexanoic acid and intermediate thereof | HAAO, HPD, HAO2 | TSHR 1023/4885DPP4 581/4885MMP2 1536/4885 |
| US-20030114352-A1 | Depot preparations | FABP4, LIPE, GPR119 | TSHR 1311/4885DPP4 161/4885MMP2 3352/4885 |
| US-20030176507-A1 | Production method of (R) -3 hydroxy-3- (2-phenylethyl) hexanoic acid and intermediate thereof | HAAO, HPD, HAO2 | TSHR 1086/4885DPP4 582/4885MMP2 1436/4885 |
| US-20110086868-A1 | SPECIFIC INHIBITORS FOR VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS | KDR, FLT4, FLT1 | TSHR 914/4885DPP4 1709/4885MMP2 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.